- Home
- RRX vs DVA Comparison
RRX vs DVA Comparison
Compare RRX & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRX
- DVA
- Stock Information
- Founded
- RRX 1955
- DVA 1994
- Country
- RRX United States
- DVA United States
- Employees
- RRX N/A
- DVA N/A
- Industry
- RRX
- DVA Misc Health and Biotechnology Services
- Sector
- RRX
- DVA Health Care
- Exchange
- RRX Nasdaq
- DVA Nasdaq
- Market Cap
- RRX 9.6B
- DVA 9.4B
- IPO Year
- RRX 1987
- DVA 1995
- Fundamental
- Price
- RRX $147.12
- DVA $124.80
- Analyst Decision
- RRX Strong Buy
- DVA Hold
- Analyst Count
- RRX 10
- DVA 3
- Target Price
- RRX $174.80
- DVA $151.00
- AVG Volume (30 Days)
- RRX 710.6K
- DVA 654.7K
- Earning Date
- RRX 10-29-2025
- DVA 10-29-2025
- Dividend Yield
- RRX 0.93%
- DVA N/A
- EPS Growth
- RRX 22.50
- DVA 5.71
- EPS
- RRX 3.87
- DVA 9.76
- Revenue
- RRX $5,872,300,000.00
- DVA $13,317,965,000.00
- Revenue This Year
- RRX N/A
- DVA $5.95
- Revenue Next Year
- RRX $3.83
- DVA $3.60
- P/E Ratio
- RRX $38.92
- DVA $12.96
- Revenue Growth
- RRX N/A
- DVA 5.14
- 52 Week Low
- RRX $90.56
- DVA $122.93
- 52 Week High
- RRX $185.28
- DVA $179.60
- Technical
- Relative Strength Index (RSI)
- RRX 52.51
- DVA 39.30
- Support Level
- RRX $143.60
- DVA $126.57
- Resistance Level
- RRX $153.68
- DVA $130.82
- Average True Range (ATR)
- RRX 5.22
- DVA 2.49
- MACD
- RRX 0.53
- DVA 0.16
- Stochastic Oscillator
- RRX 65.77
- DVA 23.69
About RRX Regal Rexnord Corporation
Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The four operating segments include Commercial Systems, Industrial Systems, Climate Solutions, and Motion Control Solutions.
About DVA DaVita Inc.
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.